查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951904

獸用原料藥市場分析及預測（至2035年）：類型、產品、服務、技術、組件、應用、形式、最終用戶和功能

Veterinary API Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, Form, End User, Functionality
出版日期: | 出版商: Global Insight Services | 英文 395 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計獸用原料藥市場規模將從2024年的117億美元成長到2034年的196億美元，複合年成長率約為4.9%。獸用原料藥市場涵蓋專為動物用藥品配製的活性藥物成分（API）。這些原料藥是獸藥的核心，用於治療各種動物疾病和健康問題。推動市場成長的因素包括寵物主人數量的增加、人們對畜牧業健康意識的提高以及獸醫領域的創新治療方法。主要趨勢包括針對新興疾病開發先進的原料藥以及整合永續的生產方法，以滿足對有效且安全的動物健康解決方案日益成長的需求。

由於寵物主人數量不斷增加以及對動物保健需求日益成長，獸用活性藥物原料藥市場預計將穩定擴張。製藥領域是推動市場成長的主要動力，其中抗感染劑和抗寄生蟲藥物佔據主導地位，這主要得益於人們對感染疾病日益成長的關注。抗發炎藥物緊隨其後，反映出人們對動物疼痛管理的日益重視。在生物製藥領域，疫苗表現最佳，這主要受醫療保健趨勢的推動。單株抗體提供標靶治療方案，並已成為重要的細分市場。營養補充劑也日益受到關注，因為益生菌和維生素有助於改善寵物的健康和表現。伴侶動物市場佔據了主要市場佔有率，這主要得益於寵物人性化以及寵物護理產品優質化。畜牧業活性藥物成分市場展現出巨大潛力，這主要歸功於人們對食品安全和永續農業的日益關注。向有機和天然產品的轉變正在影響活性藥物成分的開發，並凸顯了獸用保健領域創新的必要性。策略聯盟和研發投資對於抓住市場機會至關重要。

市場區隔
類型 合成的、生物來源的、半合成的
產品 抗生素、消炎藥、驅蟲藥、疫苗和營養補充劑
服務 契約製造、客製合成、包裝和法規支持
科技 發酵、化學合成、生物技術
成分 活性成分、添加劑
目的 伴侶動物、牲畜和水產養殖
形式 固態、液體、粉末
終端用戶 獸醫院、動物診所、研究機構
功能 治療、預防和診斷

動物醫藥成分市場呈現市場佔有率、定價策略和創新產品發布之間動態互動的特徵。各公司正透過具競爭力的定價和新產品的推出，進行策略定位，以期獲得更大的市場佔有率。這項策略的驅動力源自於寵物數量成長和畜牧健康管理日益重要，因而帶動了獸藥需求的成長。產業相關人員不斷完善產品系列，以滿足不斷變化的市場需求，創造出競爭與合作並存的市場環境。競爭標竿分析顯示，主要企業正透過策略聯盟和併購來爭取主導。監管因素，尤其是在北美和歐洲，對市場動態的塑造起著至關重要的作用。這些法規確保了產品的安全性和有效性，並影響企業的市場准入和擴大策略。目前，市場正經歷研發活動的激增，旨在開發符合嚴格監管標準的先進活性藥物成分。上述分析表明，市場正處於強勁的成長軌道，盈利相關人員豐厚的回報。

主要趨勢和促進因素：

受寵物主人數量不斷成長和動物健康意識提升日益增強的推動，獸用原料藥市場正經歷顯著成長。動物性食品需求的成長進一步促進了這一趨勢。消費者健康意識的提高促使人們更加關注這些產品的品質和安全。獸醫學技術的進步也是關鍵促進因素。藥物製劑和給藥系統的創新正在提高動物治療的有效性。這些進展吸引了投資，並促進了製藥公司和獸醫診所之間的合作。此外，個人化獸醫學的趨勢正在加速發展。基於基因分析和先進診斷技術的客製化治療方案日益普及，為專注於客製化獸醫解決方案的公司創造了機會。旨在促進動物健康的監管支持和政府主導的措施正在加速市場擴張。這些措施在新興國家尤其明顯，因為畜牧業是這些國家經濟發展的關鍵驅動力。符合這些法規結構的公司能夠更好地掌握市場機會。最後，通用感染疾病的日益增加凸顯了獸用活性藥物原料藥的重要性。這促使人們加強研發力度，致力於預防和控制這些疾病。隨著相關人員將動物和公眾健康置於優先地位，預計市場將持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 合成
    • 生物來源
    • 半合成
  • 市場規模及預測：依產品分類
    • 抗生素
    • 抗發炎藥
    • 殺寄生蟲劑
    • 疫苗
    • 營養補充品
  • 市場規模及預測：依服務分類
    • 契約製造
    • 客製合成
    • 包裝
    • 監管支持
  • 市場規模及預測：依技術分類
    • 發酵
    • 化學合成
    • 生物技術
  • 市場規模及預測：依組件分類
    • 活性成分
    • 添加劑
  • 市場規模及預測：依應用領域分類
    • 伴侶動物
    • 家畜
    • 水產養殖
  • 市場規模及預測：依類型
    • 固體的
    • 液體
    • 粉末
  • 市場規模及預測：依最終用戶分類
    • 獸醫診所
    • 動物診所
    • 研究所
  • 市場規模及預測：依功能分類
    • 治療
    • 預防性藥物
    • 診斷

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Huvepharma
  • Norbrook Laboratories
  • Phibro Animal Health
  • Sequent Scientific
  • Ceva Sante Animale
  • Vetoquinol
  • Zagro
  • Kernfarm
  • KRKA
  • Dechra Pharmaceuticals
  • Boehringer Ingelheim Vetmedica
  • Virbac
  • Elanco Animal Health
  • Bimeda
  • Hipra
  • Biogenesis Bago
  • Biovet
  • MSD Animal Health
  • Neogen Corporation
  • Ashish Life Science

第9章：關於我們

簡介目錄
Product Code: GIS24882

Veterinary API Market is anticipated to expand from $11.7 billion in 2024 to $19.6 billion by 2034, growing at a CAGR of approximately 4.9%. The Veterinary API Market encompasses active pharmaceutical ingredients specifically formulated for animal health products. These APIs are integral to veterinary medicines, addressing a range of animal diseases and health conditions. The market is driven by increased pet ownership, livestock health awareness, and innovations in veterinary therapeutics. Key trends include the development of advanced APIs for emerging diseases and the integration of sustainable production practices, catering to the rising demand for effective and safe animal health solutions.

The Veterinary API Market is poised for robust expansion, driven by increasing pet ownership and demand for animal healthcare. The pharmaceuticals segment dominates, with anti-infectives and parasiticides leading due to rising concerns about zoonotic diseases. Anti-inflammatory drugs follow closely, reflecting the growing awareness of pain management in animals. Within the biologics segment, vaccines are the top performers, propelled by preventative healthcare trends. Monoclonal antibodies are emerging as a significant sub-segment, offering targeted therapeutic solutions. Nutritional supplements are gaining traction, with probiotics and vitamins enhancing pet wellness and performance. Companion animals represent a major market share, driven by the humanization of pets and the premiumization of pet care products. Livestock APIs show potential, with increasing focus on food safety and sustainable farming practices. The shift towards organic and natural products is influencing API development, emphasizing the need for innovation in veterinary therapeutics. Strategic partnerships and investments in R&D are critical for capturing market opportunities.

Market Segmentation
TypeSynthetic, Biological, Semi-Synthetic
ProductAntibiotics, Anti-inflammatory, Parasiticides, Vaccines, Nutritional Supplements
ServicesContract Manufacturing, Custom Synthesis, Packaging, Regulatory Support
TechnologyFermentation, Chemical Synthesis, Biotechnology
ComponentActive Ingredients, Excipients
ApplicationCompanion Animals, Livestock, Aquaculture
FormSolid, Liquid, Powder
End UserVeterinary Hospitals, Veterinary Clinics, Research Institutes
FunctionalityTherapeutic, Preventive, Diagnostic

The Veterinary API Market is characterized by a dynamic interplay of market share, pricing strategies, and innovative product launches. Companies are strategically positioning themselves to capture greater market share through competitive pricing and the introduction of novel products. This approach is catalyzed by the rising demand for veterinary pharmaceuticals, driven by the increasing pet ownership and the growing importance of livestock health. Industry players are continually enhancing their product portfolios to meet the evolving needs of the market, fostering a competitive yet collaborative environment. Competition benchmarking reveals a landscape where key players vie for dominance through strategic alliances and mergers. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics. These regulations ensure product safety and efficacy, thereby influencing market entry and expansion strategies. The market is witnessing a surge in research and development activities, aimed at creating advanced APIs to meet stringent regulatory standards. This analytical landscape underscores a robust growth trajectory, promising lucrative opportunities for stakeholders.

Geographical Overview:

The Veterinary API market is witnessing dynamic growth across various regions, each exhibiting unique prospects. North America leads with robust advancements in animal healthcare and substantial investments in veterinary pharmaceuticals. The region's focus on pet ownership and livestock health fuels demand for high-quality APIs. Europe closely follows, driven by stringent regulations promoting animal welfare and sustainable farming practices. In Asia Pacific, the market is burgeoning, propelled by rising disposable incomes and increasing awareness of animal health. Countries like India and China are emerging as lucrative markets due to their expanding livestock sectors and growing pet populations. Latin America presents promising opportunities, with Brazil and Argentina investing in veterinary healthcare to enhance livestock productivity. The Middle East & Africa are also gaining traction, recognizing the importance of veterinary APIs in improving animal health and supporting agricultural economies. These regions are increasingly investing in veterinary infrastructure, highlighting the market's potential for substantial growth.

The Veterinary API Market is significantly influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, firms are increasingly investing in local production capabilities to mitigate tariff impacts and reduce dependency on imports. China, under export constraints, is fostering indigenous API development to ensure market resilience. Taiwan, pivotal in API manufacturing, faces geopolitical vulnerabilities amid US-China tensions. Globally, the veterinary API sector is robust, driven by rising pet ownership and livestock health awareness. By 2035, the market is anticipated to grow through strategic regional collaborations and technological advancements. Meanwhile, Middle East conflicts continue to disrupt global supply chains, influencing energy prices and operational costs, thereby indirectly affecting production and distribution efficiencies in the veterinary sector.

Key Trends and Drivers:

The Veterinary API Market is experiencing notable growth, driven by the increasing pet ownership and awareness of animal health. This trend is further bolstered by the rising demand for animal-derived food products. As consumers become more health-conscious, there is a heightened focus on ensuring the quality and safety of these products. Technological advancements in veterinary medicine are also a significant driver. Innovations in drug formulation and delivery systems are enhancing therapeutic outcomes for animals. This progress is attracting investment and fostering partnerships between pharmaceutical companies and veterinary clinics. Furthermore, the trend towards personalized veterinary care is gaining traction. Tailored treatments based on genetic profiling and advanced diagnostics are becoming more prevalent. This shift is creating opportunities for companies specializing in customized veterinary solutions. Regulatory support and government initiatives promoting animal health are catalyzing market expansion. These efforts are particularly evident in emerging economies, where the livestock sector is crucial for economic development. Companies that align with these regulatory frameworks are well-positioned to capitalize on market opportunities. Lastly, the increasing prevalence of zoonotic diseases underscores the importance of veterinary APIs. This has led to a surge in research and development activities aimed at preventing and controlling such diseases. The market is poised for continuous growth as stakeholders prioritize animal and public health.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by Form
  • 2.8 Key Market Highlights by End User
  • 2.9 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Synthetic
    • 4.1.2 Biological
    • 4.1.3 Semi-Synthetic
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Antibiotics
    • 4.2.2 Anti-inflammatory
    • 4.2.3 Parasiticides
    • 4.2.4 Vaccines
    • 4.2.5 Nutritional Supplements
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Manufacturing
    • 4.3.2 Custom Synthesis
    • 4.3.3 Packaging
    • 4.3.4 Regulatory Support
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Fermentation
    • 4.4.2 Chemical Synthesis
    • 4.4.3 Biotechnology
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Active Ingredients
    • 4.5.2 Excipients
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Companion Animals
    • 4.6.2 Livestock
    • 4.6.3 Aquaculture
  • 4.7 Market Size & Forecast by Form (2020-2035)
    • 4.7.1 Solid
    • 4.7.2 Liquid
    • 4.7.3 Powder
  • 4.8 Market Size & Forecast by End User (2020-2035)
    • 4.8.1 Veterinary Hospitals
    • 4.8.2 Veterinary Clinics
    • 4.8.3 Research Institutes
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Therapeutic
    • 4.9.2 Preventive
    • 4.9.3 Diagnostic

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 Form
      • 5.2.1.8 End User
      • 5.2.1.9 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 Form
      • 5.2.2.8 End User
      • 5.2.2.9 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 Form
      • 5.2.3.8 End User
      • 5.2.3.9 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 Form
      • 5.3.1.8 End User
      • 5.3.1.9 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 Form
      • 5.3.2.8 End User
      • 5.3.2.9 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 Form
      • 5.3.3.8 End User
      • 5.3.3.9 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 Form
      • 5.4.1.8 End User
      • 5.4.1.9 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 Form
      • 5.4.2.8 End User
      • 5.4.2.9 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 Form
      • 5.4.3.8 End User
      • 5.4.3.9 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 Form
      • 5.4.4.8 End User
      • 5.4.4.9 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 Form
      • 5.4.5.8 End User
      • 5.4.5.9 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 Form
      • 5.4.6.8 End User
      • 5.4.6.9 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 Form
      • 5.4.7.8 End User
      • 5.4.7.9 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 Form
      • 5.5.1.8 End User
      • 5.5.1.9 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 Form
      • 5.5.2.8 End User
      • 5.5.2.9 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 Form
      • 5.5.3.8 End User
      • 5.5.3.9 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 Form
      • 5.5.4.8 End User
      • 5.5.4.9 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 Form
      • 5.5.5.8 End User
      • 5.5.5.9 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 Form
      • 5.5.6.8 End User
      • 5.5.6.9 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 Form
      • 5.6.1.8 End User
      • 5.6.1.9 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 Form
      • 5.6.2.8 End User
      • 5.6.2.9 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 Form
      • 5.6.3.8 End User
      • 5.6.3.9 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 Form
      • 5.6.4.8 End User
      • 5.6.4.9 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 Form
      • 5.6.5.8 End User
      • 5.6.5.9 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Huvepharma
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Norbrook Laboratories
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Phibro Animal Health
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Sequent Scientific
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Ceva Sante Animale
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Vetoquinol
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Zagro
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Kernfarm
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 KRKA
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Dechra Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Boehringer Ingelheim Vetmedica
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Virbac
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Elanco Animal Health
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Bimeda
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Hipra
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Biogenesis Bago
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Biovet
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 MSD Animal Health
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Neogen Corporation
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Ashish Life Science
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us